Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Yahoo! Finance
Seattle, WA, April 04, 2024 (GLOBE NEWSWIRE) -- Outpace Bio , a cell therapy company that is solving the major barriers to curing solid tumors with unrivaled AI-powered protein design, today announced that nonclinical data will be presented in three poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Meeting being held April 5-10, 2024, in San Diego, CA. The upcoming presentations highlight the Company's progress in advancing lead pipeline program OPB-101, a mesothelin-specific CAR T cell therapeutic candidate engineered for unprecedented efficacy, powered by Outpace's end-to-end platform capabilities in computational protein design, synthetic biology, cell programming, & translational immunology. New data will also be presented on tumor-restricted IL-12, which is designed leveraging Outpace's OUTSMART TM technology to enhance solid tumor T cell therapies and is being advanced through a collaboration between Lyell Immunopharma and Outpace. “T
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]Seeking Alpha
- 2seventy bio appoints Eli Casdin and Charles Newton to its board of directors [Seeking Alpha]Seeking Alpha
- CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
LYEL
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- LYEL's page on the SEC website